drugset / Trial / NCT01696643

Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

NCT01696643 ↗

Phase 3 Terminated 1407 enrolled Merck & Co., Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.

Timeline

Start
2012-10-12
Primary completion
2014-07-21
Completion
2014-07-21

Outcome

Outcome not reported

Stopped: “A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met”

Drugs

EvaluationDrugModalityDoseRoute
Subject bevenopran Small molecule 0.25 mg Oral